Corvus Pharmaceuticals, Inc.
NASDAQ:CRVS
Overview | Financials
Company Name | Corvus Pharmaceuticals, Inc. |
Symbol | CRVS |
Currency | USD |
Price | 5.21 |
Market Cap | 334,780,012 |
Dividend Yield | 0% |
52-week-range | 1.3 - 10 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Richard A. Miller M.D. |
Website | https://www.corvuspharma.com |
An error occurred while fetching data.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818,
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD